VCYT insider buying and SEC filings, explained
Veracyte, Inc. · CIK 1384101
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$450K
Planned sales (10b5-1)
$21.0M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 24–Oct 27, 2026 | Planned (10b5-1) | Jens Holstein (Director) sold 15,000 shares between Sep 24 and Oct 27 at about $48.50 ($728K), marked as a 10b5-1 plan trade. Holdings down 35% to 27,471 shares. | SEC filing Filed Oct 28, 2026, 4:05 PM ET |
| Oct 27, 2026 | Planned (10b5-1) | Karin Eastham (Director) sold 14,850 shares at about $50.00 ($743K), marked as a 10b5-1 plan trade. Holdings down 59% to 10,247 shares. | SEC filing Filed Oct 28, 2026, 4:05 PM ET |
| Oct 19, 2026 | Planned (10b5-1) | Muna Bhanji (Director) sold 1,864 shares at $43.70 ($81K), marked as a 10b5-1 plan trade. Holdings down 4% to 40,854 shares. | SEC filing Filed Oct 20, 2026, 4:10 PM ET |
| Sep 21, 2026 | Planned (10b5-1) | John Leite (Global Chief Commercial Off) sold 4,015 shares at $40.00 ($161K), marked as a 10b5-1 plan trade. Holdings down 3% to 124,329 shares. | SEC filing Filed Sep 22, 2026 |
| Sep 14, 2026 | Planned (10b5-1) | Jens Holstein (Director) sold 5,000 shares at about $40.95 ($205K), marked as a 10b5-1 plan trade. Holdings down 15% to 27,471 shares. | SEC filing Filed Sep 16, 2026 |
| Sep 4, 2026 | Planned (10b5-1) | Annie McGuire (EVP, General Counsel) sold 3,254 shares at about $43.09 ($140K), marked as a 10b5-1 plan trade. Holdings down 2% to 131,160 shares. | SEC filing Filed Sep 4, 2026 |
| Sep 4, 2026 | Planned (10b5-1) | Rebecca Chambers (CFO) sold 3,652 shares at about $43.10 ($157K), marked as a 10b5-1 plan trade. Holdings down 2% to 166,025 shares. | SEC filing Filed Sep 4, 2026 |
| Sep 4, 2026 | Planned (10b5-1) | Phillip G. Febbo (Chief Scientific & Med Officer) sold 13,110 shares at about $43.05 ($564K), marked as a 10b5-1 plan trade. Holdings down 9% to 133,048 shares. | SEC filing Filed Sep 4, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | Muna Bhanji (Director) sold 1,864 shares at $42.97 ($80K), marked as a 10b5-1 plan trade. Holdings down 4% to 42,718 shares. | SEC filing Filed Sep 3, 2026 |
| Jun 18, 2026 | Planned (10b5-1) | Karin Eastham (Director) sold 3,729 shares at about $52.89 ($197K), marked as a 10b5-1 plan trade. Holdings down 20% to 15,097 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | John Leite (Global Chief Commercial Off) sold 13,975 shares at about $50.07 ($700K), marked as a 10b5-1 plan trade. Holdings down 10% to 132,305 shares. | SEC filing Filed Jun 4, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | Annie McGuire (EVP, General Counsel) sold 3,176 shares at about $49.76 ($158K), marked as a 10b5-1 plan trade. Holdings down 2% to 137,240 shares. | SEC filing Filed Jun 4, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | Rebecca Chambers (CFO) sold 3,561 shares at about $49.73 ($177K), marked as a 10b5-1 plan trade. Holdings down 2% to 173,280 shares. | SEC filing Filed Jun 4, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | Marc Stapley (CEO and Director) sold 138,051 shares at about $50.12 ($6.9M), marked as a 10b5-1 plan trade. Holdings down 24% to 440,494 shares. | SEC filing Filed Jun 4, 2026 |
| May 20, 2026 | Planned (10b5-1) | Robert S. Epstein (Director) sold 10,000 shares at about $44.01 ($440K), marked as a 10b5-1 plan trade. Holdings down 16% to 52,446 shares. | SEC filing Filed May 22, 2026 |
| May 6, 2026 | Planned (10b5-1) | Annie McGuire (SVP, General Counsel) sold 10,204 shares at about $39.03 ($398K), marked as a 10b5-1 plan trade. Holdings down 7% to 143,708 shares. | SEC filing Filed May 8, 2026 |
| Mar 4, 2026 | Planned (10b5-1) | John Leite (Chief Commercial Officer-CLIA) sold 5,260 shares at about $35.19 ($185K), marked as a 10b5-1 plan trade. Holdings down 5% to 107,580 shares. | SEC filing Filed Mar 6, 2026 |
| Mar 4, 2026 | Planned (10b5-1) | Annie McGuire (SVP, General Counsel) sold 6,658 shares at about $35.55 ($237K), marked as a 10b5-1 plan trade. Holdings down 7% to 94,706 shares. | SEC filing Filed Mar 6, 2026 |
| Mar 4, 2026 | Planned (10b5-1) | Rebecca Chambers (CFO) sold 18,341 shares at about $36.14 ($663K), marked as a 10b5-1 plan trade. Holdings down 12% to 131,196 shares. | SEC filing Filed Mar 6, 2026 |
| Mar 4, 2026 | Planned (10b5-1) | Marc Stapley (CEO and Director) sold 45,523 shares at about $35.98 ($1.6M), marked as a 10b5-1 plan trade. Holdings down 11% to 357,554 shares. | SEC filing Filed Mar 6, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Phillip G. Febbo (Chief Scientific & Med Officer) sold 13,425 shares at about $36.16 ($485K), marked as a 10b5-1 plan trade. Holdings down 10% to 117,346 shares. | SEC filing Filed Mar 4, 2026 |
| Dec 16, 2025 | Planned (10b5-1) | Annie McGuire (SVP, General Counsel) sold 10,739 shares at about $43.14 ($463K), marked as a 10b5-1 plan trade. Holdings down 14% to 67,760 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 5, 2025 | Planned (10b5-1) | Karin Eastham (Director) sold 20,000 shares at about $45.45 ($909K), marked as a 10b5-1 plan trade. Holdings down 60% to 13,554 shares. | SEC filing Filed Dec 8, 2025 |
| Dec 4, 2025 | Planned (10b5-1) | John Leite (Chief Commercial Officer-CLIA) sold 1,278 shares at $47.51 ($61K), marked as a 10b5-1 plan trade. Holdings down 2% to 82,113 shares. | SEC filing Filed Dec 4, 2025 |
| Dec 4, 2025 | Planned (10b5-1) | Annie McGuire (SVP, General Counsel) sold 1,422 shares at about $47.30 ($67K), marked as a 10b5-1 plan trade. Holdings down 2% to 78,499 shares. | SEC filing Filed Dec 4, 2025 |
| Dec 4, 2025 | Planned (10b5-1) | Rebecca Chambers (CFO) sold 13,278 shares at about $46.84 ($622K), marked as a 10b5-1 plan trade. Holdings down 11% to 109,496 shares. | SEC filing Filed Dec 4, 2025 |
| Dec 4, 2025 | Planned (10b5-1) | Marc Stapley (CEO and Director) sold 7,668 shares at about $47.09 ($361K), marked as a 10b5-1 plan trade. Holdings down 2% to 318,603 shares. | SEC filing Filed Dec 4, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | John Leite (Chief Commercial Officer-CLIA) sold 2,808 shares at $50.00 ($140K), marked as a 10b5-1 plan trade. Holdings down 3% to 86,291 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Evan/ Fa Jones (Director) sold 1,106 shares at about $50.25 ($56K), marked as a 10b5-1 plan trade. Holdings down 4% to 29,362 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 20, 2025 | Planned (10b5-1) | Jens Holstein (Director) sold 10,000 shares at about $42.36 ($424K), marked as a 10b5-1 plan trade. Holdings down 27% to 27,199 shares. | SEC filing Filed Nov 21, 2025 |
| Nov 7–10, 2025 | Sale | Jonathan Wygant (VP, Chief Accounting Officer) sold 10,920 shares between Nov 7, 2025 and Nov 10, 2025 at about $41.20 ($450K). Holdings down 22% to 38,745 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 12, 2025 |
| Nov 5, 2025 | Planned (10b5-1) | Annie McGuire (SVP, General Counsel) sold 6,466 shares at $40.00 ($259K), marked as a 10b5-1 plan trade. Holdings down 7% to 82,973 shares. | SEC filing Filed Nov 7, 2025 |
| Nov 5, 2025 | Planned (10b5-1) | Rebecca Chambers (CFO) sold 7,000 shares at $41.00 ($287K), marked as a 10b5-1 plan trade. Holdings down 5% to 126,158 shares. | SEC filing Filed Nov 7, 2025 |
| Nov 5, 2025 | Planned (10b5-1) | Karin Eastham (Director) sold 9,674 shares at about $40.02 ($387K), marked as a 10b5-1 plan trade. Holdings down 42% to 13,554 shares. | SEC filing Filed Nov 7, 2025 |
| Nov 5, 2025 | Planned (10b5-1) | Evan/ Fa Jones (Director) sold 43,196 shares at about $45.06 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 59% to 30,468 shares. | SEC filing Filed Nov 7, 2025 |
51 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow VCYT in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.